Castle Biosciences Inc (CSTL) Stock Price, Quote & News

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 866 788 9007

Website: castlebiosciences.com

Address:

1500 W. Parkwood Ave, Suite 400, Friendswood, United States

anachartanalyst Apr. 20 at 7:02 PM

$CSTL https://anachart.com/wp-content/uploads/ana_temp/1776711719_soc-img.jpg

0 · Reply

OfficialStocktwitsUser Mar. 27 at 4:42 PM

$CSTL RSI: 24.33, MACD: -1.8851 Vol: 1.16, MA20: 26.13, MA50: 31.86 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Dream2121 Mar. 16 at 1:37 PM

$CSTL Zacks Rank: 1-Strong Buy

0 · Reply

macroaxis Mar. 11 at 6:36 PM

$CSTL – Volatility Alert: Rising Options Pin Risk Signals Potential Trading Opportunities in Castle Biosciences https://www.macroaxis.com/stock-options/CSTL/Castle-Biosciences?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

TheTradeXchange Mar. 9 at 11:01 AM

$CSTL - DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

0 · Reply

BillionerOfKing Mar. 2 at 10:25 PM

$CSTL Current Stock Price: $27.98 Contracts to trade: $30.0 CSTL Mar 20 2026 Call Entry: $0.65 Exit: $1.22 ROI: 88% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 27 at 11:21 PM

$CSTL RSI: 37.66, MACD: -2.1727 Vol: 3.13, MA20: 32.93, MA50: 37.28 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StocktwitsEarnings Feb. 27 at 7:26 PM

$CSTL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -123.53% YoY • Reported revenue of $87.01M up 0.81% YoY • Castle Biosciences anticipates generating between $340M and $350M in total revenue for the full year 2026, reflecting continued growth and market opportunities.

0 · Reply

erevnon Feb. 27 at 1:59 PM

Baird maintains Castle Biosciences $CSTL at Outperform and raises the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 26 at 9:17 PM

$CSTL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -123.53% YoY • Reported revenue of $87.01M up 0.81% YoY • Castle Biosciences anticipates generating between $340M and $350M in total revenue for 2026. The company expects continued top-line performance and growth of test volumes.

0 · Reply

Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

Apr 15, 2026, 7:00 AM EDT - 10 days ago

Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

Apr 10, 2026, 7:00 AM EDT - 15 days ago

Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year

Mar 27, 2026, 9:05 AM EDT - 4 weeks ago

Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

Mar 23, 2026, 4:30 PM EDT - 4 weeks ago

Castle Biosciences Transcript: Status update

Mar 13, 2026, 11:02 AM EDT - 6 weeks ago

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

Mar 9, 2026, 7:00 AM EDT - 6 weeks ago

DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Mar 4, 2026, 4:30 PM EST - 7 weeks ago

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Mar 3, 2026, 4:30 PM EST - 7 weeks ago

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Feb 26, 2026, 4:30 PM EST - 2 months ago

Castle Biosciences Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:05 PM EST - 2 months ago

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Feb 19, 2026, 5:46 PM EST - 2 months ago

Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Feb 5, 2026, 7:00 AM EST - 2 months ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Jan 11, 2026, 4:00 PM EST - 3 months ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Dec 19, 2025, 7:00 AM EST - 4 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 7:00 AM EST - 4 months ago

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Dec 12, 2025, 7:00 AM EST - 4 months ago

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Dec 9, 2025, 7:00 AM EST - 4 months ago

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Dec 2, 2025, 1:10 PM EST - 5 months ago

Castle Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 10:00 AM EST - 5 months ago

Castle Biosciences Transcript: Stephens Annual Investment Conference

Nov 17, 2025, 7:00 AM EST - 5 months ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Nov 14, 2025, 7:00 AM EST - 5 months ago

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Nov 11, 2025, 7:00 AM EST - 5 months ago

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 8:02 AM EST - 6 months ago

Why Castle Biosciences' Rally Might Just Be Getting Started

Nov 3, 2025, 4:30 PM EST - 6 months ago

Castle Biosciences Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:07 PM EST - 6 months ago

Castle Biosciences Reports Third Quarter 2025 Results

Nov 3, 2025, 4:05 PM EST - 6 months ago

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Oct 28, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Oct 26, 2025, 3:05 PM EDT - 6 months ago

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus

Oct 24, 2025, 4:05 AM EDT - 6 months ago

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Oct 13, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Oct 1, 2025, 4:30 PM EDT - 7 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Sep 23, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

Sep 10, 2025, 10:15 AM EDT - 8 months ago

Castle Biosciences Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 7:00 AM EDT - 8 months ago

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Aug 25, 2025, 7:00 AM EDT - 8 months ago

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Aug 12, 2025, 12:30 PM EDT - 9 months ago

Castle Biosciences Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 4, 2025, 4:30 PM EDT - 9 months ago

Castle Biosciences Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:05 PM EDT - 9 months ago

Castle Biosciences Reports Second Quarter 2025 Results

Jul 29, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 25, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Jul 23, 2025, 7:00 AM EDT - 9 months ago

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Jul 17, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Jul 14, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Jun 16, 2025, 4:30 PM EDT - 11 months ago

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Jun 11, 2025, 7:00 AM EDT - 11 months ago

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Jun 4, 2025, 7:35 AM EDT - 11 months ago

Castle Biosciences Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 7:00 AM EDT - 11 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

May 29, 2025, 4:30 PM EDT - 11 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

May 21, 2025, 7:00 AM EDT - 1 year ago

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 7:00 AM EDT - 1 year ago

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

May 7, 2025, 7:00 AM EDT - 1 year ago

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 5, 2025, 4:30 PM EDT - 1 year ago

Castle Biosciences Earnings Call Transcript: Q1 2025

May 5, 2025, 4:06 PM EDT - 1 year ago

Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 1 year ago

Castle Biosciences to Acquire Previse

May 2, 2025, 4:30 PM EDT - 1 year ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Apr 30, 2025, 5:00 PM EDT - 1 year ago

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Apr 28, 2025, 7:00 AM EDT - 1 year ago

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Apr 25, 2025, 4:15 PM EDT - 1 year ago

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Mar 18, 2025, 11:15 AM EDT - 1 year ago

Castle Biosciences Transcript: KeyBanc Annual Health Care Forum 2025

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Castle Biosciences Transcript: Leerink Global Healthcare Conference 2025

Feb 27, 2025, 4:30 PM EST - 1 year ago

Castle Biosciences Earnings Call Transcript: Q4 2024

Dec 4, 2024, 10:50 AM EST - 1 year ago

Castle Biosciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 10:00 AM EST - 1 year ago

Castle Biosciences Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 11, 2024, 2:30 PM EST - 1 year ago

Castle Biosciences Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 4, 2024, 4:30 PM EST - 1 year ago

Castle Biosciences Earnings Call Transcript: Q3 2024

Sep 11, 2024, 9:05 AM EDT - 1 year ago

Castle Biosciences Transcript: Baird's 2024 Global Healthcare Conference

Aug 13, 2024, 12:30 PM EDT - 1 year ago

Castle Biosciences Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 5, 2024, 4:30 PM EDT - 1 year ago

Castle Biosciences Earnings Call Transcript: Q2 2024

May 29, 2024, 2:00 PM EDT - 2 years ago

Castle Biosciences Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 2, 2024, 4:30 PM EDT - 2 years ago

Castle Biosciences Earnings Call Transcript: Q1 2024

Apr 9, 2024, 12:45 PM EDT - 2 years ago

Castle Biosciences Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 19, 2024, 11:15 AM EDT - 2 years ago

Castle Biosciences Transcript: KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Feb 28, 2024, 4:30 PM EST - 2 years ago

Castle Biosciences Earnings Call Transcript: Q4 2023

Nov 28, 2023, 12:30 PM EST - 2 years ago

Castle Biosciences Transcript: The Piper Sandler 35th Annual Healthcare Conference

Nov 15, 2023, 11:00 AM EST - 2 years ago

Castle Biosciences Transcript: Stephens Annual Investment Conference | NASH 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Castle Biosciences Earnings Call Transcript: Q3 2023

Sep 13, 2023, 10:15 AM EDT - 2 years ago

Castle Biosciences Transcript: Baird's Global Healthcare Conference 2023

Aug 2, 2023, 4:30 PM EDT - 2 years ago

Castle Biosciences Earnings Call Transcript: Q2 2023

May 3, 2023, 4:30 PM EDT - 3 years ago

Castle Biosciences Earnings Call Transcript: Q1 2023

Feb 28, 2023, 4:30 PM EST - 3 years ago

Castle Biosciences Earnings Call Transcript: Q4 2022

Nov 2, 2022, 4:30 PM EDT - 3 years ago

Castle Biosciences Earnings Call Transcript: Q3 2022

Sep 20, 2022, 4:00 PM EDT - 3 years ago

Castle Biosciences Transcript: Investor Day 2022

Aug 7, 2022, 8:09 PM EDT - 4 years ago

Castle Biosciences Earnings Call Transcript: Q2 2022

May 9, 2022, 5:34 AM EDT - 4 years ago

Castle Biosciences Earnings Call Transcript: Q1 2022

Apr 4, 2022, 5:06 AM EDT - 4 years ago

Castle Biosciences Transcript: M&A Announcement

Feb 28, 2022, 4:41 AM EST - 4 years ago

Castle Biosciences Earnings Call Transcript: Q4 2021

Nov 7, 2021, 7:00 PM EST - 4 years ago

Castle Biosciences Earnings Call Transcript: Q3 2021

Oct 19, 2021, 7:30 AM EDT - 4 years ago

Castle Biosciences Transcript: M&A Announcement

Aug 9, 2021, 10:33 AM EDT - 5 years ago

Castle Biosciences Earnings Call Transcript: Q2 2021

May 10, 2021, 5:30 PM EDT - 5 years ago

Castle Biosciences Earnings Call Transcript: Q1 2021

Apr 27, 2021, 7:30 AM EDT - 5 years ago

Castle Biosciences Transcript: M&A Announcement

Mar 8, 2021, 4:30 PM EST - 5 years ago

Castle Biosciences Earnings Call Transcript: Q4 2020

Nov 9, 2020, 4:30 PM EST - 5 years ago

Castle Biosciences Earnings Call Transcript: Q3 2020

Oct 28, 2020, 4:30 PM EDT - 5 years ago

Castle Biosciences Transcript: Investor Update

Sep 2, 2020, 4:30 PM EDT - 6 years ago

Castle Biosciences Transcript: Investor Update

Aug 10, 2020, 4:30 PM EDT - 6 years ago

Castle Biosciences Earnings Call Transcript: Q2 2020

May 11, 2020, 4:30 PM EDT - 6 years ago

Castle Biosciences Earnings Call Transcript: Q1 2020

anachartanalyst Apr. 20 at 7:02 PM

$CSTL https://anachart.com/wp-content/uploads/ana_temp/1776711719_soc-img.jpg

0 · Reply

OfficialStocktwitsUser Mar. 27 at 4:42 PM

0 · Reply

Dream2121 Mar. 16 at 1:37 PM

$CSTL Zacks Rank: 1-Strong Buy

0 · Reply

macroaxis Mar. 11 at 6:36 PM

0 · Reply

TheTradeXchange Mar. 9 at 11:01 AM

$CSTL - DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

0 · Reply

BillionerOfKing Mar. 2 at 10:25 PM

0 · Reply

OfficialStocktwitsUser Feb. 27 at 11:21 PM

0 · Reply

StocktwitsEarnings Feb. 27 at 7:26 PM

0 · Reply

erevnon Feb. 27 at 1:59 PM

Baird maintains Castle Biosciences $CSTL at Outperform and raises the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 26 at 9:17 PM

$CSTL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -123.53% YoY • Reported revenue of $87.01M up 0.81% YoY • Castle Biosciences anticipates generating between $340M and $350M in total revenue for 2026. The company expects continued top-line performance and growth of test volumes.

0 · Reply

Dream2121 Feb. 26 at 8:48 PM

$CSTL $40 in 40 minutes.

1 · Reply

OletaPinchback332 Feb. 21 at 6:42 AM

$CSTL Castle Biosciences provides diagnostic testing. Revenue growth depends on clinical adoption. Margins improve with scale.

0 · Reply

Flibenson Feb. 19 at 2:56 PM

$CSTL https://www.prnewswire.com/news-releases/merlin-cp-gep-becomes-the-first-and-only-gene-expression-profile-gep-test-recommended-by-nccn-cutaneous-melanoma-guidelines-to-assess-metastatic-risk-302692470.html

0 · Reply

Flibenson Feb. 19 at 2:47 PM

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

$NVO's Wegovy gets EC nod for higher dose — but is it enough to boost the stock? NVO shares down 9.9% in six months, lagging the industry’s 27.4% growth New 7.2 mg Wegovy dose shows promising weight loss results, yet the stock carries a Zacks Rank #5 (Strong Sell) Some better-ranked stocks are $HRMY, $ALKS, and $CSTL. Opportunity or risk? Full analysis here 👉 https://www.zacks.com/stock/news/2871232/eu-approves-novo-nordisks-higher-dose-wegovy-for-obesity-patients?cid=sm-stocktwits-2-2871232-body-33960&ADID=SYND_STOCKTWITS_TWEET_2_2871232_BODY_33960

0 · Reply

DonaldLefort773 Feb. 18 at 12:36 PM

$CSTL Diagnostics platform benefiting from preventative healthcare adoption; reimbursement stability is critical.

0 · Reply

commoncentsinvestor Feb. 6 at 5:53 PM

$CSTL ABEO selling for $5 with almost $4 in cash, new FDA approved Zevaskyn now on market. Going to fly.

0 · Reply

CapitalPilot Feb. 4 at 2:25 PM

$CSTL is a clinical-stage biotech developing cell therapies for cancer; it is a high-risk, early-stage company in the competitive cell therapy space.

1 · Reply

OfficialStocktwitsUser Jan. 28 at 8:58 PM

$CSTL RSI: 44.49, MACD: 0.8802 Vol: 1.31, MA20: 40.41, MA50: 39.19 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechNoir Jan. 26 at 3:23 PM

$CSTL new 52 week

0 · Reply

SuperGreenToday Jan. 23 at 7:36 PM

$CSTL Share Price: $41.69 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $5.10 – $6.30 Target Zone: $9.57 – $11.69 Potential Upside: 77% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BioTechNoir Jan. 22 at 3:27 PM

$CSTL new 52 week

0 · Reply

Market Cap	717.71M
Revenue (ttm)	344.23M
Net Income (ttm)	-24.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7.02%
Debt to Equity Ratio	0.02

Volume	341,300
Avg Vol	358,950
Day's Range	N/A - N/A
Shares Out	30.30M
Stochastic %K	51%
Beta	1.18
Analysts	Strong Sell
Price Target	$47.25